![](images/graphics/blank.gif)
When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: A real-world study from Taiwan
11
lượt xem 3
download
lượt xem 3
download
![](https://tailieu.vn/static/b2013az/templates/version1/default/images/down16x21.png)
The addition of anti-angiogenesis drugs to epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) or chemotherapy in patients with EGFR-mutant non–small cell lung cancer (NSCLC) can improve disease control. We conducted a study to evaluate the efficacy of combination therapeutic strategies and identify patients who could benefit from combination therapy.
Chủ đề:
Bình luận(0) Đăng nhập để gửi bình luận!
![](images/graphics/blank.gif)
CÓ THỂ BẠN MUỐN DOWNLOAD